JPWO2021097365A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021097365A5 JPWO2021097365A5 JP2022527937A JP2022527937A JPWO2021097365A5 JP WO2021097365 A5 JPWO2021097365 A5 JP WO2021097365A5 JP 2022527937 A JP2022527937 A JP 2022527937A JP 2022527937 A JP2022527937 A JP 2022527937A JP WO2021097365 A5 JPWO2021097365 A5 JP WO2021097365A5
- Authority
- JP
- Japan
- Prior art keywords
- hla
- ras
- molecule
- antigen
- restricted peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 564
- 230000035772 mutation Effects 0.000 claims description 409
- 102000025171 antigen binding proteins Human genes 0.000 claims description 158
- 108091000831 antigen binding proteins Proteins 0.000 claims description 158
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 claims description 125
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 claims description 125
- 239000000427 antigen Substances 0.000 claims description 112
- 102000036639 antigens Human genes 0.000 claims description 112
- 108091007433 antigens Proteins 0.000 claims description 112
- 210000004027 cell Anatomy 0.000 claims description 77
- 102220404671 HLA-A*11:01 Human genes 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 52
- 102210042925 HLA-A*02:01 Human genes 0.000 claims description 40
- 102210024049 HLA-A*03:01 Human genes 0.000 claims description 32
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 31
- 108091008874 T cell receptors Proteins 0.000 claims description 29
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 29
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 201000011510 cancer Diseases 0.000 claims description 19
- 102000016914 ras Proteins Human genes 0.000 claims description 19
- 102210009893 HLA-C*01:02 Human genes 0.000 claims description 18
- 102210047469 A*02:01 Human genes 0.000 claims description 17
- 102000040430 polynucleotide Human genes 0.000 claims description 15
- 108091033319 polynucleotide Proteins 0.000 claims description 15
- 239000002157 polynucleotide Substances 0.000 claims description 15
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 11
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 102210024048 HLA-A*01:01 Human genes 0.000 claims description 8
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 5
- 201000005787 hematologic cancer Diseases 0.000 claims description 5
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 5
- 239000012636 effector Substances 0.000 claims description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 4
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 4
- 108010021727 HLA-A*24:02 antigen Proteins 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 102200006531 rs121913529 Human genes 0.000 claims description 3
- 102200006537 rs121913529 Human genes 0.000 claims description 3
- 102200006539 rs121913529 Human genes 0.000 claims description 3
- 102200006538 rs121913530 Human genes 0.000 claims description 3
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 claims description 2
- 230000003325 follicular Effects 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 claims description 2
- 239000000833 heterodimer Substances 0.000 claims description 2
- 210000002861 immature t-cell Anatomy 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 210000004877 mucosa Anatomy 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 210000003289 regulatory T cell Anatomy 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 72
- 108010058607 HLA-B Antigens Proteins 0.000 description 72
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 33
- 108010075704 HLA-A Antigens Proteins 0.000 description 33
- 102210042961 A*03:01 Human genes 0.000 description 26
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 24
- 108010052199 HLA-C Antigens Proteins 0.000 description 24
- 102210048101 A*01:01 Human genes 0.000 description 20
- 102210041563 HLA-A*31:01 Human genes 0.000 description 15
- 108010020515 HLA-A*68 antigen Proteins 0.000 description 12
- 102210009883 HLA-B*07:02 Human genes 0.000 description 12
- 102210024050 HLA-B*08:01 Human genes 0.000 description 12
- 102210009880 HLA-B*27:05 Human genes 0.000 description 12
- 239000000203 mixture Substances 0.000 description 10
- 102210024054 HLA-C*03:04 Human genes 0.000 description 9
- 102210009885 HLA-C*08:02 Human genes 0.000 description 9
- 102210048099 C*08:02 Human genes 0.000 description 8
- 238000002823 phage display Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 102210009887 HLA-B*13:02 Human genes 0.000 description 6
- 102210024051 HLA-B*15:01 Human genes 0.000 description 6
- 102210042926 HLA-B*44:02 Human genes 0.000 description 6
- 102210024055 HLA-C*03:03 Human genes 0.000 description 6
- 102210009886 HLA-C*04:01 Human genes 0.000 description 6
- 102210042928 HLA-C*05:01 Human genes 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 5
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 5
- 230000004068 intracellular signaling Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- LVFOCONPPZIORE-UHFFFAOYSA-N 2-[[2-[[2-[2-[[2-[[2-[[2-[[2-[[2-(2,6-diaminohexanoylamino)-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]acetyl]amino]propanoylamino]-3-methylbutanoyl]amino]acetyl]amino]-3-methylbutanoic acid Chemical compound NCCCCC(N)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(C(C)C)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(C)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(C(C)C)C(O)=O LVFOCONPPZIORE-UHFFFAOYSA-N 0.000 description 4
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 4
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 102200105349 rs587778720 Human genes 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 102210009891 HLA-A*25:01 Human genes 0.000 description 3
- 102220404670 HLA-A*33:01 Human genes 0.000 description 3
- 108010034115 HLA-A29 antigen Proteins 0.000 description 3
- 102210009888 HLA-B*14:02 Human genes 0.000 description 3
- 108091058535 HLA-B*35:08 Proteins 0.000 description 3
- 102210039566 HLA-B*39:01 Human genes 0.000 description 3
- 102220436838 HLA-B*51 Human genes 0.000 description 3
- 102210024052 HLA-B*57:01 Human genes 0.000 description 3
- 102210009890 HLA-C*02:02 Human genes 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 102210048103 B*18:01 Human genes 0.000 description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
- 102100029974 GTPase HRas Human genes 0.000 description 2
- 102100039788 GTPase NRas Human genes 0.000 description 2
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 2
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 206010069755 K-ras gene mutation Diseases 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 102220053950 rs121913238 Human genes 0.000 description 2
- 102200006520 rs121913240 Human genes 0.000 description 2
- 102200006525 rs121913240 Human genes 0.000 description 2
- 102200007373 rs17851045 Human genes 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- -1 wells Substances 0.000 description 2
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 102210042962 C*03:04 Human genes 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 101000691214 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 50S ribosomal protein L44e Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000002203 alpha-beta t lymphocyte Anatomy 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962936303P | 2019-11-15 | 2019-11-15 | |
| US62/936,303 | 2019-11-15 | ||
| US202063030774P | 2020-05-27 | 2020-05-27 | |
| US63/030,774 | 2020-05-27 | ||
| PCT/US2020/060605 WO2021097365A2 (en) | 2019-11-15 | 2020-11-13 | Antigen-binding proteins targeting shared neoantigens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023502625A JP2023502625A (ja) | 2023-01-25 |
| JPWO2021097365A5 true JPWO2021097365A5 (pt) | 2023-11-21 |
Family
ID=75912393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022527937A Pending JP2023502625A (ja) | 2019-11-15 | 2020-11-13 | 共有新抗原を標的にする抗原結合タンパク質 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230041030A1 (pt) |
| EP (1) | EP4058484A4 (pt) |
| JP (1) | JP2023502625A (pt) |
| KR (1) | KR20220098379A (pt) |
| CN (1) | CN115175934A (pt) |
| AU (1) | AU2020384374A1 (pt) |
| CA (1) | CA3157411A1 (pt) |
| IL (1) | IL292535A (pt) |
| WO (1) | WO2021097365A2 (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3428194T3 (pl) | 2017-07-14 | 2022-01-17 | Immatics Biotechnologies Gmbh | Ulepszona cząsteczka polipeptydu o podwójnej specyficzności |
| KR20210119468A (ko) * | 2019-01-25 | 2021-10-05 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 돌연변이체 ras를 표적화하기 위한 조성물 및 방법 |
| JP2022521513A (ja) | 2019-02-20 | 2022-04-08 | フレッド ハッチンソン キャンサー リサーチ センター | Ｒａｓネオ抗原に特異的な結合タンパク質およびその使用 |
| AU2022270361A1 (en) | 2021-05-05 | 2023-11-16 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| WO2023288203A2 (en) * | 2021-07-12 | 2023-01-19 | Ludwig Institute For Cancer Research Ltd | T cell receptors specific for tumor-associated antigens and methods of use thereof |
| AU2022346048A1 (en) * | 2021-09-17 | 2024-04-04 | Gritstone Bio, Inc. | Kras neoantigen therapies |
| WO2023086435A1 (en) * | 2021-11-10 | 2023-05-19 | Memorial Sloan-Kettering Cancer Center | T cell receptors targeting q61-comprising ras mutations and uses thereof |
| WO2023139257A1 (en) * | 2022-01-21 | 2023-07-27 | T-Knife Gmbh | Antigen recognizing construct that binds specific peptide with determinable affinity and t cell receptor having antigenic specificity for kras as well as corresponding nucleic acid sequence, vector, host cell, pharmaceutical composition and kit |
| WO2023173024A2 (en) * | 2022-03-10 | 2023-09-14 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of coronary artery disease by reducing activity of cross-reactive t cells |
| WO2024036166A1 (en) * | 2022-08-08 | 2024-02-15 | The University Of North Carolina At Chapel Hill | Bioorthogonal t cell receptor molecules and methods of making and using the same |
| WO2024039576A2 (en) * | 2022-08-19 | 2024-02-22 | Memorial Sloan-Kettering Cancer Center | T cell receptors targeting ras mutations and uses thereof |
| CN116350758A (zh) * | 2023-03-16 | 2023-06-30 | 郑州大学 | 肿瘤共享新抗原表位肽或其编码核酸在制备药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2771349B1 (en) * | 2011-09-16 | 2020-02-26 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| WO2013190090A1 (en) * | 2012-06-21 | 2013-12-27 | Philip Morris Products S.A. | Gene signatures for classifying and grading lung cancer |
| ES2965689T3 (es) * | 2014-11-26 | 2024-04-16 | Us Health | Receptores de células T anti-KRAS mutado |
| WO2016154047A2 (en) * | 2015-03-20 | 2016-09-29 | Memorial Sloan-Kettering Cancer Center | Monoclonal antigen-binding proteins to intracellular oncogene products |
| TWI806815B (zh) * | 2015-05-20 | 2023-07-01 | 美商博德研究所有限公司 | 共有之ｇａｔａ３相關之腫瘤特異性新抗原 |
| CN111328288A (zh) * | 2017-08-18 | 2020-06-23 | 磨石肿瘤生物技术公司 | 靶向共同抗原的抗原结合蛋白 |
| EP3796927A4 (en) * | 2018-05-23 | 2022-04-20 | Gritstone bio, Inc. | SHARED ANTIGENS |
-
2020
- 2020-11-13 JP JP2022527937A patent/JP2023502625A/ja active Pending
- 2020-11-13 CN CN202080085181.6A patent/CN115175934A/zh active Pending
- 2020-11-13 IL IL292535A patent/IL292535A/en unknown
- 2020-11-13 AU AU2020384374A patent/AU2020384374A1/en active Pending
- 2020-11-13 KR KR1020227019577A patent/KR20220098379A/ko unknown
- 2020-11-13 WO PCT/US2020/060605 patent/WO2021097365A2/en unknown
- 2020-11-13 EP EP20886309.2A patent/EP4058484A4/en active Pending
- 2020-11-13 CA CA3157411A patent/CA3157411A1/en active Pending
-
2022
- 2022-05-13 US US17/744,354 patent/US20230041030A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021500852A5 (pt) | ||
| JP7295795B2 (ja) | 免疫調節ポリペプチドならびに関連する組成物および方法 | |
| CN110088133B (zh) | 抗独特型抗体及相关方法 | |
| JP7184645B2 (ja) | 修飾キメラ受容体ならびに関連する組成物および方法 | |
| US20230041030A1 (en) | Antigen-binding proteins targeting shared neoantigens | |
| KR20190104528A (ko) | Car-t 세포들 투여를 결정하는 방법 | |
| JP2017504324A5 (pt) | ||
| KR20140127845A (ko) | 항원-형질감염된 t 세포와 함께 사용되는 이중특이적 항체 분자 및 의약에서의 이들의 용도 | |
| WO2018187791A1 (en) | Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods | |
| CN112110995A (zh) | 肿瘤新抗原多肽及其用途 | |
| Zou et al. | Role of MICA in the immune response to transplants | |
| JPWO2021097365A5 (pt) | ||
| EP3095792A1 (en) | T cell receptor with specificity for myeloperoxidase peptide and uses thereof | |
| JP2021520209A (ja) | 癌患者における腫瘍抗原を検出するための診断アッセイ | |
| JP2023062079A (ja) | Ｃｄ４３の固有のシアログリコシル化がん関連エピトープを標的化するモノクローナル抗体 | |
| Schmittnaegel et al. | A new class of bifunctional major histocompatibility class I antibody fusion molecules to redirect CD8 T cells | |
| WO2021092094A1 (en) | Antigen-binding proteins targeting shared neoantigens | |
| JP2009278927A (ja) | Ｔ細胞受容体を模倣する抗体断片及びその製造方法 | |
| US20220050114A1 (en) | Methods for mass spectrometry analysis of engineered cell compositions | |
| JP7355650B2 (ja) | 細胞表面グリコシル化を評価するための方法 | |
| CN107435065B (zh) | 鉴定灵长类抗体的方法 | |
| US11518811B2 (en) | Human antibody and fragments thereof for use in the treatment of gastric cancer (GC) and other types of tumours expressing the MICA protein (MHC class I chain-related protein A gene) | |
| EP4223782A1 (en) | Novel t cell receptors and immune therapy using the same for the treatment of cancer | |
| US20240180969A1 (en) | Polypeptides targeting hla-a*11 and methods of use thereof | |
| CN117999097A (zh) | 用于产生个人化癌症免疫疗法的方法 |